Weight-Loss Medications and Hair Loss: What Is the Role of Nutrition?

Hair loss has been increasingly reported by people using medications for obesity treatment, particularly GLP-1 receptor agonists and related therapies, such as semaglutide and tirzepatide.

But do these medications actually cause hair loss?

Recent studies suggest an association between these treatments and certain types of alopecia, but the available evidence does not yet establish that GLP-1–based medications directly cause hair loss.

The explanation is likely more complex and may involve several factors, including rapid weight loss, reduced food intake, metabolic changes, and potential nutritional deficiencies.

What Have the Studies Found?

One of the studies analyzed data from nearly 394,000 individuals, including more than 20,000 people who had used a GLP-1 receptor agonist.

When the drug class was analyzed as a whole, GLP-1 receptor agonist use was associated with an 18% higher odds of any alopecia diagnosis and an 80% higher odds of androgenetic alopecia.

However, no statistically significant increase in alopecia areata or telogen effluvium was found when all GLP-1 medications were analyzed together.

The results also differed according to the specific medication. Semaglutide showed a significant association with androgenetic alopecia, whereas tirzepatide was not significantly associated with any of the alopecia subtypes evaluated in that study.

Therefore, current evidence does not suggest a uniform effect across all medications in this class.

What Happens to Hair During Rapid Weight Loss?

One of the main mechanisms proposed by researchers is telogen effluvium.

Hair follicles naturally cycle through different phases. Under conditions of significant physiological stress, a larger number of follicles may prematurely leave the growth phase and enter the resting phase. Some time later, these hairs begin to shed.

Telogen effluvium is already well recognized after systemic illnesses, surgery, highly restrictive diets, and substantial weight loss.

The scientific literature on GLP-1–based therapies suggests that rapid weight loss may represent an acute metabolic stress capable of triggering telogen effluvium.

Where Does Nutrition Fit In?

This is particularly important for patients receiving pharmacological treatment for obesity.

GLP-1–based medications can substantially reduce appetite. When patients eat considerably less without adequate nutritional planning, their total intake of energy, protein, vitamins, and minerals may also decrease.

Researchers have proposed nutritional deficiencies as one of several possible mechanisms contributing to the association between GLP-1 therapies and hair loss, together with rapid weight loss and metabolic or hormonal changes.

Hair follicles are metabolically active structures. Hair growth and maintenance depend on an adequate supply of energy, protein, and micronutrients.

In clinical practice, when hair loss occurs during weight loss, it is therefore important to evaluate the overall quality of the diet and, when clinically indicated, investigate possible nutritional deficiencies.

This does not mean that everyone using a GLP-1 medication should take supplements to prevent hair loss.

Supplementation should be individualized according to nutritional and medical assessment.

Not All Hair Loss Is the Same

Another important finding is that different forms of alopecia should not be considered a single condition.

In the scientific review, among the studies that characterized the type of hair loss, androgenetic alopecia and telogen effluvium were among the patterns reported.

Androgenetic alopecia differs from telogen effluvium. It is associated with individual predisposition and progressive miniaturization of the hair follicles.

It is possible that major metabolic and hormonal changes associated with weight loss may make previously subtle androgenetic alopecia more noticeable.

Telogen effluvium, on the other hand, typically causes more diffuse hair shedding and is usually associated with an identifiable physiological or metabolic trigger.

For this reason, determining which type of hair loss is occurring is essential before deciding on treatment.

What About Alopecia Areata?

Alopecia areata is an immune-mediated disease that typically causes well-defined patches of hair loss.

In the large retrospective study, GLP-1 receptor agonist use was not associated with a statistically significant increase in the odds of alopecia areata.

The authors even discuss the hypothesis that the anti-inflammatory properties of GLP-1 receptor agonists could potentially contribute to this finding. However, this remains a hypothesis and requires further investigation.

Do Weight-Loss Injections Cause Hair Loss?

Based on current evidence, we cannot make such a definitive statement.

Studies demonstrate a signal of association, but association does not prove causation.

The scientific literature also highlights important limitations. In many observational reports, patients did not undergo detailed dermatological assessment or trichoscopy, and the specific type of alopecia was not adequately characterized.

There is also insufficient information regarding the timing of hair loss, its relationship with medication dose, the amount and speed of weight loss, and what happens when treatment is continued or discontinued.

At present, a possible multifactorial pathway can be considered:

GLP-1–based treatment → reduced appetite and food intake → rapid weight loss and/or inadequate nutrient intake → metabolic stress → changes in the hair follicle cycle → increased hair shedding.

Other mechanisms directly or indirectly related to these medications cannot yet be excluded.

What Should You Do If Hair Loss Begins During Treatment?

The first step should not be to immediately stop the medication or start taking vitamins without medical guidance.

The underlying cause needs to be investigated.

Clinical assessment should consider the rate and magnitude of weight loss, dietary quantity and quality, protein intake, gastrointestinal symptoms such as nausea or vomiting, and other medical conditions or medications that could contribute to hair loss.

When clinically appropriate, laboratory investigation of potential nutritional deficiencies may also be necessary.

If hair loss persists or there is suspicion of androgenetic alopecia, alopecia areata, or another scalp disorder, a dermatological evaluation may be recommended.

The Most Important Message

Obesity treatment should not be evaluated solely by the number of kilograms lost.

The quality of weight loss matters.

Very rapid weight loss accompanied by inadequate food intake may have consequences beyond hair health, including loss of muscle mass and nutritional deficiencies.

For this reason, patients using medications for obesity treatment should receive appropriate attention to their diet, protein intake, nutritional status, body composition, and rate of weight loss.

Hair loss may be a sign that some aspect of the weight-loss process needs to be reassessed.

The goal should not simply be to lose weight.

The goal is to lose weight while preserving health, muscle mass, and adequate nutritional status.

Scientific References:

Ching LM, Guirguis CA, Tung JK. Associations Between GLP-1 Receptor Agonists and Alopecia: A Multi-Centre Retrospective Analysis and Public Interest Trends. JEADV Clinical Practice, 2025.

Rojas Lopez RF, Lynett Barrera D, Amaya Muñoz MC, Saavedra Diaz MP. Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review. Cureus. 2025;17(8):e90021.

]